Mitochon Pharmaceuticals Overview

  • Founded
  • 2014

Founded
  • Status
  • Private

  • Employees
  • 4

Employees
  • Latest Deal Type
  • Later Stage VC

  • (Upcoming)
  • Investors
  • 4

Mitochon Pharmaceuticals General Information

Description

Developer of drugs intended to modulate the mitochondria for serious neurodegenerative diseases with significant unmet medical needs. The company's drugs are primarily focused on neurodegenerative and neuromuscular diseases, enabling healthcare providers to treat Huntington's, Batten's Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer's Disease, Parkinson's Disease, and severe burns.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 970 Cross Lane
  • Blue Bell, PA 19422
  • United States
+1 (215) 000-0000

Mitochon Pharmaceuticals Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mitochon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC Upcoming Generating Revenue
6. Later Stage VC 13-Jul-2021 00.00 00.000 Completed Clinical Trials - Phase 1
5. Early Stage VC 30-Nov-2019 00.00 00.000 Completed Clinical Trials - Phase 1
4. Angel (individual) 21-Dec-2017 00000 00.000 Completed Generating Revenue
3. Grant 03-Oct-2017 000 00.000 Completed Generating Revenue
2. Early Stage VC 17-May-2016 $1.6M $2.35M Completed Generating Revenue
1. Early Stage VC 31-Mar-2015 $750K $750K Completed Generating Revenue
To view Mitochon Pharmaceuticals’s complete valuation and funding history, request access »

Mitochon Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of drugs intended to modulate the mitochondria for serious neurodegenerative diseases with significant unmet m
Drug Discovery
Blue Bell, PA
4 As of 2022
00.000
00000 00000

000000

lore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui off
0000000000000
Boston, MA
00 As of 0000
00000
0000000000 0 00000

000000

t. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pari
0000 000000000
Barcelona, Spain
00 As of 0000
0000
000000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mitochon Pharmaceuticals Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cardurion Pharma Venture Capital-Backed Boston, MA 00 00000 0000000000 0 00000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 0000 000000000000 0000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
0000000 000 Venture Capital-Backed San Diego, CA 00 000.00 00000000000 000.00
00000000 Venture Capital-Backed New York, NY 00 0000 00000000000 0000
You’re viewing 5 of 13 competitors. Get the full list »

Mitochon Pharmaceuticals Patents

Mitochon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3016465-A1 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases Pending 07-Mar-2016 000000000
EP-3426233-A1 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases Pending 07-Mar-2016 000000000
AU-2017229224-A1 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases Active 07-Mar-2016 00000000000
AU-2017229224-B2 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases Active 07-Mar-2016 00000000000
EP-3426233-A4 Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases Pending 07-Mar-2016 A61K31/5375
To view Mitochon Pharmaceuticals’s complete patent history, request access »

Mitochon Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
Robert Alonso Co-Founder, Chief Executive Officer, President & Board Member
John Geisler Ph.D Co-Founder , Chief Scientific Officer & Board Member
Marcus Keep MD Acting Chief Medical Officer
You’re viewing 3 of 6 executive team members. Get the full list »

Mitochon Pharmaceuticals Board Members (5)

Name Representing Role Since
Anthony Jannetta Mitochon Pharmaceuticals Board Member 000 0000
Jennifer Hartt Ben Franklin Technology Partner of Southeastern Pennsylvania Board Observer 000 0000
John Geisler Ph.D Mitochon Pharmaceuticals Co-Founder , Chief Scientific Officer & Board Member 000 0000
Robert Alonso Mitochon Pharmaceuticals Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Wolfgang Baiker MD Self Board Member 000 0000
To view Mitochon Pharmaceuticals’s complete board members history, request access »

Mitochon Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mitochon Pharmaceuticals Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
HNW Angel Angel Group Minority 000 0000 000000 0
Michael J. Fox Foundation Limited Partner 000 0000 000000 0
Ben Franklin Technology Partner of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
YT Angels Other Minority 000 0000 000000 0
To view Mitochon Pharmaceuticals’s complete investors history, request access »